-
-
Overview
-
Specificity: Detects human Beta Amyloid. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Gantenerumab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Bulk Human IgG1 Isotype Control (IB1) [ICH2254]
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL methodPlease contact us at for specific academic pricing.
Background
RUO gantenerumab is a monoclonal antibody for the treatment of Alzheimer’s disease being developed by Hoffmann-La Roche pharmaceuticals. Gantenerumab binds to and clears aggregated beta amyloid fibers. A phase III clinical trial of gantenerumab was stopped early because of a lack efficacy.
-
- Properties
- Applications
-
Overview